Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<